Update README.md

README.md

@@ -29,6 +29,38 @@ dataset_info:
   download_size: 15202058
   dataset_size: 46041453
 ---
-# Dataset Card for "anli_r3_en"
+# XNLI
 
-[More Information needed](https://github.com/huggingface/datasets/blob/main/CONTRIBUTING.md#how-to-contribute-to-the-dataset-cards)
+- Source: https://huggingface.co/datasets/anli
+- Num examples: 
+  - 100,459 (train)
+  - 1,200 (validation)
+  - 1,200 (test)
+- Language: English
+
+```python
+from datasets import load_dataset
+
+load_dataset("vietgpt/anli_r3_en")
+```
+
+- Format for NLI task
+
+```python
+def preprocess(sample):
+    premise = sample['premise']
+    hypothesis = sample['hypothesis']
+    label = sample['label']
+
+    if label == 0:
+        label = "entailment"
+    elif label == 1:
+        label = "neutral"
+    else:
+        label = "contradiction"
+    return {'text': f'<|startoftext|><|premise|> {premise} <|hypothesis|> {hypothesis} <|label|> {label} <|endoftext|>'}
+
+"""
+<|startoftext|><|premise|> TOKYO, Dec 18 (Reuters) - Japan’s Shionogi & Co said on Tuesday that it has applied to health regulators in the United States, Canada and Europe for approval of its HIV drug Dolutegravir. Shionogi developed Dolutegravir with a Viiv Healthcare, an AIDS drug joint venture between GlaxoSmithKline and Pfizer, in exchange for its rights to the drug. <|hypothesis|> The article was written on December 18th. <|label|> entailment <|endoftext|>
+"""
+```